Abstract: Cosmetic or dermatological compositions for washing and/or antidandruff treatment of hair and/or scalp comprising at least one antidandruff agent chosen from pyridinethione salts, at least 1% by weight of at least one hydroxy acid, and at least one amphoteric surface-active agent or nonionic surface-active agent of the alkyl(poly)glycoside type.

Abstract: A nutritional supplement for use in managing carbohydrates and enhancing anabolism in mammals is described. The nutritional supplement contains regulated amounts of niacin, chromium, and vanadium, and optionally thiamin, riboflavin, magnesium, and zinc. These vitamins and minerals mimic and/or enhance the physiological effects of insulin in the body. A method of using the composition is also described.

Abstract: A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part comprises an acid and an optional oxidizable colorant, and wherein the first part, the second part, or both the first and second parts comprise an alpha olefin sulfonate.

Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.

Abstract: The invention relates to the production of food and can be used to obtain food additives, biologically active food additives. The invention discloses the use of vicinal dithioglicol of general chemical formula RCH(SH)CH(SH)R1 as a food additive or a biologically active food additive having the property of binding carbonil compounds present in food products and the human body according to the reaction resulting in the formation of cyclic thioacetal or ketal which are easily removable from the human body as well as able to form complexes with ions of bivalent metals providing a physiologically beneficial effect on the transportation of said ions through sell membranes, on the glycolysis process, on the enzymatic catalysis process, on the catabolism of carbohydrate moiety of amino acids and on thiol-disulfide equilibrium in the metabolism of amino acids. As well as inhibiting undesirable processes in food products and human body.

Abstract: Carboxylic acid fluorides having a boiling point of preferably less than 100° C. are suitable for use as pesticides. Acetyl fluoride is highly suitable, and Chlorodifluoroacetyl fluoride and trifluoroacetyl fluoride are also very useful. Mixtures of carboxylic acid fluoride pesticides and other pesticides are also disclosed.

Abstract: A means of sex discriminant birth whereby the sex discriminant birth can be performed at such a high possibility as almost perfectly ensuring the desired sex discrimination. Sex discriminant birth can he achieved by treating ova or sperm with a solution of a mixture of a basic amino acid with an inorganic alkali salt in in vitro fertilization or in vivo fertilization.

Abstract: The present invention provides a hair growth agent and a hair fostering shampoo that have N-methyltaurine as an essential ingredient, and have hair growth period extending effects, and moreover are capable of giving hair fitness and body and giving hair a feeling of volume. Moreover, the present invention also provides a cell activating agent and a hair fitness/body improving agent that are blended into hair cosmetics.

Abstract: The invention provides methods of inhibiting cerebral amyloid angiopathy. The invention further provides methods of treating a disease state characterized by cerebral amyloid angiopathy in a subject.

Abstract: A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body.

Abstract: This invention concerns compounds for inhibiting intracellular signal transduction, especially intracellular signal transduction mediated by one or more molecular interactions involving a phosphotyrosine-containing protein. This invention also relates to pharmaceutical compositions containing the compounds and prophylactic and therapeutic methods involving pharmaceutical and veterinary administration of the compounds. The compounds are of the formula as defined herein.

Abstract: A method of preparing organic acids (fulvic, humic, and ulmic) for use as an electrolyte for producing high ionizations of precious metals (such as silver) which entails leaching out the organic acid from its source, stabilizing the organic acid first with ascorbic acid followed by sodium benzoate, removing cations, and using the organic acid as an electrolyte. A precious metal (such as silver) is used as a sacrificial electrode in this electrolyte. A non-sacrificial electrode could either be the same precious metal or an inert non-precious metal (titanium or graphite carbons). If the same material is used for the non-sacrificial electrode as for the sacrificial electrode, the size of each electrode may be about the same. If different material is used for the non-sacrificial electrode, its size should be larger that of the sacrificial electrode. Current at about 2 or more volts is applied to the electrodes and the ionization process begins yielding high concentrations of ionized precious metals.

Abstract: The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases.

Abstract: A treatment for cancer is provided. The treatment may include administering a therapeutic amount of L-histidine, D-cycloserine, quisqualic acid or suramin or analogs thereof.

Abstract: The present invention relates to an oral drug delivery system, and in particular to modified amino acids and modified amino acid derivatives for use as a delivery system of sensitive agents such as bioactive peptides. The modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form durg containing microspheres. These mixtures are suitable for oral administration of biologically active agents to animals. Methods for the preparation of such amino acids are also disclosed.

Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

Abstract: A method for enhancing activity of enzyme at an elevated temperature which comprises adding a substance exhibiting chaperone function such as a saccharide to a reaction mixture containing the enzyme. The method can improve activity of enzymes more easily and more effectively and hence afford increased enzyme activity at an elevated temperature.

Abstract: The present invention relates to a composition containing retinol and a compound capable of screening out UVA radiation corresponding to formula (I): 1

Abstract: A topical composition comprising: (a) petroselinic acid and/or derivatives thereof; (b) a phenolic compound and/or mixtures thereof; and (c) a dermatologically acceptable vehicle. The product is particularly useful for treating wrinkles and soothing sensitive skin.

Abstract: A method of treating pain by the co-administration of an antidepressant together with one or more precursors or inducers of neurotransmitters, particularly amino acids selected from L-phenylalanine, L-tyrosine, L-tryptophan and L-DOPA.

Abstract: The present invention relates to a pharmaceutical composition which is appropriate for eradication or extermination of Helicobacter pylori wherein [4-[4-(4-methylbenzyloxycarbonyl)phenyl[phenyl trans-4-guanidinomethylcyclohexanecarboxylate or an acid addition salt thereof are compounded and it also relates to a complex consisting them.

Abstract: Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.

Abstract: Biological fouling is effectively controlled in water systems and process streams through the addition of hops extract.

Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The .compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.

Abstract: A method including administering a beverage composition suitable for human consumption including effective amounts of the following solubilized components, a calcium compound, an organic acid in an amount up to the equivalent amount of a calcium of the calcium compound, an isoflavone, and inulin wherein the effective amounts are sufficient to reduce the risk of bone density loss and are solubilized by a stabilizing agent including one or more of maltol, carrageenan and maltodextrin, and xanthan gum.

Abstract: The present invention relates to a method for the production of natural taurine-enriched milk using biological metabolism, in which a precursor for synthesis of taurine is prepared in the shape of a pallet or matrix resistant to degradation in the rumen of ruminants and added to a feedstuff, such that biosynthesis of taurine is induced by stimulation of a substrate. According to the method of the present invention, methionine or methionine precursor which is the precursor for taurine synthesis is coated with additives including an inert material and a filler, and thus protected from a rumen pH and an enzymatic action of rumen microorganisms. As a result, problems of the rumen degradation and the metabolism obstruction can be solved. Taurine-enriched milk according to the present invention contains taurine at a higher concentration than general milk, and hence, can be effectively used for the preparation of functional baby foods, and for the preparation of health foods.

Abstract: This invention provides compounds of formula I having the structure 1

Abstract: The invention concerns the use of compounds of general formula (I): (X)n1,Y,(Z)n2 wherein n1 and n2 represent 0 or 1; X represents a natural amino acid, in particular an amino acid selected among ornithine, arginine, lysine, histidine or glutamine; Y represents a keto acid of formula (II): R—CO—COOH wherein R represents —CH3, —CH2—CH3, —CH(CH3)2, —CH(CH3)—CH2—CH3, —CH2—CH(CH3)2, —CH2)2—COOH, —CH2)3—COOH; Z represents: a natural amino acid selected in particular among ornithine, arginine, lysine, histidine or glutamine; or a polyamine selected in particular among cadaverine, putrescine, spermidine, spermine or agmatine. Said compounds are useful for preparing a medicine for treating human or animal pathologies wherein are involved silent neurons, such as pathologies of the digestive tract, the bladder and the biliary ducts.

Abstract: The creation of a limpid, stable micro-emulsion from liquid lipophilic materials of vegetable origin, specifically, essential oils, using an ecologically optimized solubilizing agent consisting of a mixture of one ethoxylated vegetable oil and at least one supplemental tensio-active comprising an anionic tensio-active derived from another vegetable oil and/or a non-ionic co-tensio-active. The micro-emulsion retains the original active properties of the essential oils in addition to the specific individual properties of the solubilizing agent or the mixture thereof with the lipophilic vegetable materials. Applications: all the applications of essential oils and those conferred by the addition of the specific tensio-actives.

Abstract: The present invention provides compositions and methods for the solubilization of poorly soluble drugs such as triterpenes like betulinic acid and/its derivatives in pharmaceutically acceptable liquid vehicles that avoid use of potentially toxic solvents that are often used for the solubilization of poorly soluble drugs. In the compositions of this invention the drugs remain physically and chemically stable and can be administered intravascularly without undue toxicity from undissolved drug and/or from the solvent vehicles at a drug dose meant to be effective to exhibit clinically significant anticancer activity.

Abstract: A method for increasing the effectiveness of a biocide is described. In the method, at least one biocide and at least one diethanolamide are applied to a substrate or aqueous system subject to the growth of microorganisms. The diethanolamide is applied in an amount effective to increase the biocidal activity of the biocide. Biocidal compositions are described where the biocide and the diethanolamide are present in a combined amount effective to control the growth of at least one microorganism. Methods for controlling the growth of microorganisms on various substrates and in various aqueous systems are also described. The combination of the biocide and the diethanolamide is particularly useful as a biocide in the leather industry, the lumber industry, the papermaking industry, the textile industry, the agricultural industry, and the coating industry, as well as in industrial process waters.

Abstract: The present invention relates to methods for decreasing the resistance of microbial strains to antiinfectives such an antibiotics and antifungals by altering the ATP gradient across biological membranes. The altering of the ATP gradient across biological membranes is achieved through the inhibition of ecto-phosphatase activity and/or ABC transporter molecule activity which may be useful to reduce resistance in bacteria and yeast to aid in the treatment of certain infections and disease and to lower the concentration of antiinfectives necessary to inhibit the growth of microbial strains.

Abstract: The present invention provides an active heat shock protein inducing factor which is capable of inducing expression of heat shock proteins such as Hsp70 and Hsp27 on-demand in living mammalian cells. The induction and intracellular expression of such heat shock proteins provides major protection for the cells against injurious stresses and can be used therapeutically for treatment of conditions and disorders caused by cell death via apoptosis or necrosis.

Abstract: The instant invention provides &bgr;3 adrenergic receptor agonists of structural Formula (I), 1

Abstract: The invention provides methods of inhibiting A&bgr;-induced neuronal cell death. The invention further provides methods of providing neuroprotection to a subject and methods of treating a disease state characterized by A&bgr;-induced neuronal cell death in a subject. Methods of inhibiting p75 receptor mediated neuronal cell death, as well as methods of treating a disease state in a subject characterized by p75 receptor mediated neuronal cell death are provided.

Abstract: The present invention relates to compounds of the general formula I.

Abstract: An acidic aqueous hydrogen peroxid solution is provided, with improved disinfectant activity. Concentrated solutions preferably contain up to about 8% and as-used concentrations contain about 0.5% peroxide. The solution also contains from 0.1 to 5.0% of at least one acid compound, e.g. phosphoric and/or a phosphonate with from 1 to 5 phosphonic acid groups, and from 0.02 to 5% of at least one anionic surfactant. The surfactant is selected from C8 to C16-alkyl aryl sulphonic acids, sulphonated C12 to C22 carboxylic acids, C8 to C22-alkyl diphenyl oxide sulphonic acids, naphthalene sulphonic acids, C8 to C22 alkyl sulphonic acids, and alkali metal and ammonium salts thereof, and alkali metal C8 to C18 alkyl sulphates, and mixtures thereof. Most preferably the solution has an emulsifier, e.g. a salt of an alkylated diphenyl oxide. The solution may also contain corrosion inhibitors and/or lower alcohols.

Abstract: Cosmetic or dermatological preparations which have a pH of >5, with a content of physiologically compatible sulfinic acids.

Abstract: Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.

Abstract: This invention relates to the method of using specially formulated neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.

Abstract: The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.

Abstract: Methods for treating diseases associated with toxicity of Apolipoprotein E (“apoE”). Specifically, the present invention relates to new methods for treating a mammal having a condition associated with toxicity of apolipoprotein E cleavage fragments containing residues 130-169, comprising administering to said mammal a pharmacologically effective amount of compound or a pharmaceutically acceptable sale, derivative or fragment thereof to interfere with the receptor-binding site associated with residues 130-169 of the apolipoprotein E molecule in said mammal.

Abstract: Picornaviral 3C protease inhibitors of formula I, obtainable by chemical synthesis, that inhibit or block the biological activity of the picornaviral 3C protease are described. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses.

Abstract: This invention provides a dietary supplement comprising L-Carnitine (or its functional analogues such as Acetyl-Carnitine or Proprionyl-1-Carnitine), Coenzyme Q10 and Taurine for the correction of the abnormality in mitochondrial energetics in cardiac failure and certain other diseases. A high protein nutritional feeding supplementation with Cysteine, Creatine, Vitamin E (RRR-d-alpha-tocopherol), Vitamin C (ascorbic acid), Selenium, and Thiamin in may be added.

Abstract: Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described.

Abstract: A method and composition are disclosed utilizing the pure (S,R) isomer of formoterol, which is a bronchodilator with reduced adverse effects. (S,R)-Formoterol may be conveniently and safely formulated for aerosol administration.

Abstract: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-&agr; comprising an effective amount of a TNF-&agr; inhibitor, as well as a method for treatment of such disorders, and the use of TNF-&agr; inhibitors in the preparation of pharmaceutical compositions for such treatment.

Abstract: A method for disinfecting a substrate is provided. The substrate is contacted with a biocidal effective amount of a composition of (a) at least one quaternary ammonium carbonate, bicarbonate, or any combination thereof; (b) a solvent selected from the group consisting of water and propylene glycol; and (c) optionally, a surfactant.

Abstract: A composition useful as a dietary supplement for providing potassium, calcium, and citrate is presented, as well as processes for producing the composition, and methods for using the composition as a dietary supplement. Administration of the composition counters bone loss associated with aging or menopause by providing bioavailable calcium and, simultaneously, delivering alkali load. In addition, administration of the composition produces a substantial increase in urinary citrate, which counters kidney-stone formation.

Abstract: A plant treatment composition for application of an anionic exogenous chemical substance such as glyphosate to foliage of a plant is provided.